Emphasize Adherence to Help Boost Hep C Cure Rates

January 2016

More hepatitis C patients will now be treated...due to updated guidelines.

Most patients will get one or two of the new oral meds, Daklinza (daclatasvir)...Harvoni (ledipasvir/sofosbuvir)...Galexos (simeprevir)...Sovaldi (sofosbuvir)...Technivie (ombitasvir/paritaprevir/ritonavir)...or Holkira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir).

Expect most patients to be treated for 12, 16, or 24 weeks...often based on whether they have cirrhosis or have been treated before.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Antibiotics Recommend Alternatives to Quinolones
Cardiology Reassure Stent Patients that Clopidogrel is an Important Heart Med
NSAIDs Explain Topical NSAIDs May Work as Well as Oral NSAIDs
Hypertension Considering Suggesting Lower Systolic BP Goals in SOME Patients
Hepatitis C Emphasize Adherence to Help Boost Hep C Cure Rates
Antipsychotics Be Aware that Abilify is Linked to Uncontrollable Gambling and Hypersexuality
Vaccines Don't Stop Statins in Patients Getting the Flu Vaccine
Asthma Suggest Just a Single Dose of Dexamethasone for Asthma Exacerbations
Diarrhea Don't Recommend Dukoral (oral cholera vaccine) for Traveller's Diarrhea
Supplements Watch Our for Supplement Brand Name Extensions
Contraceptives Suggest Stopping Hormonal Contraceptives by Age 55

Emphasize Adherence to Help Boost Hep C Cure Rates

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents